Emerging therapies: Angiogenesis inhibitors for ovarian cancer

Expert Opinion on Emerging Drugs

Volumn 20, Issue 2, 2015, Pages 331-346

  Jackson, Amanda L ^a   Eisenhauer, Eric L ^a   Herzog, Thomas J ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Fallopian tube cancer; Ovarian cancer; Primary peritoneal cancer; Tyrosine kinase inhibitors; VEGF

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; ERIBULIN; GEMCITABINE; GOG 262; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; NINTEDANIB; OLAPARIB; PACLITAXEL; PAZOPANIB; SARACATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANEMIA; ANTIANGIOGENIC THERAPY; ANUS FISSURE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY HEMORRHAGE; LEUKOPENIA; LUNG EMBOLISM; MAINTENANCE THERAPY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; WOUND DEHISCENCE; ANIMAL; DISEASE FREE SURVIVAL; DRUG DESIGN; FEMALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; PATIENT SELECTION; QUALITY OF LIFE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG DESIGN; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATIENT SELECTION; QUALITY OF LIFE;

EID: 84930022866     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1036739     Document Type: Review

References (78)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
2. Yazici S, Kim SJ, Busby JE, et al. Dual inhibition of the epiDermal growth factor and vascuLar endothelial growth factor phosphoryLation for antivascuLar therapy of human prostate cancer in the prostate of nuDe mice. Prostate 2005;65(3):203-15
3. Katsumata N, YasuDa M, Isonishi S, et al. Long-term results of dose-Dense paclitaxel and carbopLatin versus conventional paclitaxel and carbopLatin for treatment of adVanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-Label trial. Lancet Oncol 2013;14(10):1020-6
4. MitsiaDes CS, KotouLa V, PouLaki V, et al. EpiDermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006;91(9):3662-6
5. Heymach JV, Nilsson M, Blumenschein G, et al. EpiDermal growth factor receptor inhibitors in Development for the treatment of non-smacelung cancer. Clin Cancer Res 2006;12(14 Pt 2):4441s-5s
6. Adjei AA. Targeting multiple signal transduction pathways in lung cancer. Clin Lung Cancer 2005;7(Suppl 1):S39-44
7. Eisenhauer EL, Zanagnolo V, Cohn DE, et al. A phase II study of gemcitabine, carbopLatin and bevacizumab for the treatment of pLatinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2014;134(2):262-6
8. Younes MN, Yigitbasi OG, Park YW, et al. AntivascuLar therapy of human follicuLar thyroid cancer experimental bone metastasis by blockaDe of epiDermal growth factor receptor and vascuLar growth factor receptor phosphoryLation. Cancer Res 2005;65(11):4716-27
9. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Ce2004;6(5):507-16
10. LinDahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-Deficient mice. Science 1997;277(5323):242-5
11. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cispLatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130(1):64-8
12. BenDeJC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRIbevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17(12):1486-95
13. Liu J, Barry W, Birrer M, et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor oLaparib and the antiangiogenic cediranib against oLaparib alone in recurrent pLatinum-sensitive ovarian cancer. J Clin Oncol 2014;32(5s Suppl):abstract LBA5500
14. Raja F, Perren T, Embleton A, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in reLapsed pLatinum sensitive ovarian cancer: results of the ICON6 trial. Int J Gynecol Cancer 2013;23(8 Suppl 1):47
15. Cohn R the surgeon and the cost of medical care. Am J Surg 1985;150(1):2-8
16. Engler PE, Cohn JD, Del Guercio LR. A cost-effective system for obtaining comprehensive cardiovascuLar information on the critically ipatient. Med Instrum 1977;11(5):311-14
17. Cohn MM. Smoke Abatement at Low Cost. Am J Public Health Nations Health 1933;23(7):668-72
18. du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A randomized pLacebo-controlled GCIG/ENGOTINTERGROUP phase III trial of stanDard frontline chemotherapy+/-ninteDanib for adVanced ovarian cancer. Int J Gynecol Cancer 2013;23(8 Suppl 1):7
19. Oehler-Janne C, Jochum W, Riesterer O, et al. Hypoxia moduLation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and reLated allograft tumor moDels. Mol Cancer Ther 2007;6(9):2496-504
20. Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascuLar therapy for ovarian carcinoma. Clin Cancer Res 2007;13(14):4209-17
21. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cispLatin and intravenous paclitaxel plus bevacizumab as adjuVant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 2011;29(35):4662-8
22. Rouzier R, Morice P, Floquet A, et al. A randomized, open-Label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuVant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal aDenocarcinoma, initially unresectable. J Clin Oncol 2014;32(5s Suppl):abstract TPS5614
23. Barlesi F, Breen D. [Targeting HER pathway in head and neck and thoracic cancers]. BuCancer 2009;96(Suppl 1):S35-43
24. WeDel SA, Mickuckyte A, Juengel E, et al. [Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cecarcinoma cells]. Urologe A 2008;47(9):1175-81
25. Okamoto K, Neureiter D, Alinger B, et al the dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocelluLar carcinoma xenografts in nuDe mice. Int J Oncol 2008;33(4):733-42
26. Chura JC, Van Iseghem K, Downs LS Jr, et al. Bevacizumab plus cyclophosphamiDe in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007;107(2):326-30
27. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamiDe in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26(1):76-82
28. Matulonis UA, Pereira L, Liu J, et al. Sequential bevacizumab and oral cyclophosphamiDe for recurrent ovarian cancer. Gynecol Oncol 2012;126(1):41-6
29. Del Carmen MG, Micha J, SmaL, et al. A phase II clinical trial of pegyLated liposomal doxorubicin and carbopLatin plus bevacizumab in patients with pLatinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2012;126(3):369-74
30. Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegyLated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 2011;122(2):233-7
31. Verschraegen CF, Czok S, Muller CY, et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with pLatinum-And taxane-resistant ovarian cancer. Ann Oncol 2012;23(12):3104-10
32. Wenham RM, LapolLa J, Lin HY, et al. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior pLatinumbased chemotherapy. Gynecol Oncol 2013;130(1):19-24
33. Herzog TJ, Monk BJ, Rose PG, et al. A phase II trial of oxalipLatin, docetaxel, and bevacizumab as first-line therapy of adVanced cancer of the ovary, peritoneum, and fallopian tube. Gynecol Oncol 2014;132(3):517-25
34. Ling HT, Muggia F, Speyer JL, et al. A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer. J Clin Oncol 2014;32(5s suppl):abstract 5564
35. McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with pLatinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;117(16):3731-40
36. Tillmanns TD, Lowe MP, Walker MS, et al. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, pLatinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2013;128(2):221-8
37. IkeDa Y, Takano M, ODa K, et al. Weekly administration of bevacizumab, gemcitabine, and oxalipLatin in patients with recurrent and refractory ovarian cancer: A preliminary result of 19 cases. Int J Gynecol Cancer 2013;23(2):355-60
38. Backes FJ, Richardson DL, McCann GA, et al. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer 2013;23(5):833-8
39. Barnett JC, Alvarez Secord A, Cohn DE, et al. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. Cancer 2013;119(20):3653-61
40. SmerDel MP, Steffensen KD, Waldstrom M, et al the predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010;118(2):167-71
41. Lee JM, Sarosy GA, Annunziata CM, et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and Decreased toxicity. Br J Cancer 2010;102(3):495-9
42. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohns disease perianal fistuLae. Gastroenterology 2001;120(7):1640-56
43. Chambers SK, Clouser MC, Baker AF, et al. Overexpression of tumor vascuLar endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010;16(21):5320-8
44. Hagemann AR, Novetsky AP, Zighelboim I, et al. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2013;131(3):535-40
45. Tew WP, SiM, McMeekin DS, et al. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). J Clin Oncol 2014;32(5s Suppl):abstract 5546
46. IkeDa Y, Takano M, Sasaki N, et al. Effect of weekly administration of bevacizumab, eribulin, and oxalilpLatin in patients with heavily pretreated serous ovarian carcinoma. J Clin Oncol 2013;31(Suppl):abstract e16506
47. Barbarroja N, Torres LA, Rodriguez-Ariza A, et al. AEE788 is a vascuLar endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Exp Hematol 2010;38(8):641-52
48. Hirte HW, ViDal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008;26(15S Suppl):5521
49. Venkatesan P, Das S, Krishnan MM, et al. Effect of AEE788 and/or Celecoxib on colon cancer cemorphology using adVanced microscopic techniques. Micron 2010;41(3):247-56
50. du Bois A, Vergote I, Wimberger P, et al. Open-Label feasibility study of pazopanib, carbopLatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: A phase I/II trial of the AGO study group. Br J Cancer 2012;106(4):629-32
51. FriedLanDer M, Hancock KC, Rischin D, et al. A Phase II, open-Label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
52. du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus pLacebo in women who have not progressed after first-line chemotherapy for adVanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGOOVAR16). J Clin Oncol 2013;31(Suppl):abstract LBA5503
53. du Bois A, Huober J, Stopfer P, et al. A phase I open-Label dose-escaLation study of oral BIBF 1120 combined with stanDard paclitaxel and carbopLatin in patients with adVanced gynecological malignancies. Ann Oncol 2010;21(2):370-5
54. KarLan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, pLacebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30(4):362-71
55. Polcher M, Eckhardt M, Coch C, et al. Sorafenib in combination with carbopLatin and paclitaxel as neoadjuVant chemotherapy in patients with adVanced ovarian cancer. Cancer Chemother Pharmacol 2010;66(1):203-7
56. Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013;130(1):25-30
57. Matei D, SiMW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial. J Clin Oncol 2011;29(1):69-75
58. Ramasubbaiah R, Perkins SM, SchilDer J, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123(3):499-504
59. Behera R, Thomas SM, Mensa-Wilmot K. New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrob Agents Chemother 2014;58(4):2202-10
60. McNeish IA, LeDermann JA, Webber L, et al. A randomised, pLacebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in pLatinum-resistant ovarian, fallopian tube or primary peritoneal cancerDagger. Ann Oncol 2014;25(10):1988-95
61. Juretzka M, Hensley ML, Tew W, et al. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol 2008;29(6):568-72
62. SchilDer RJ, SiMW, Lee RB, et al. Phase II evaluation of imatinib mesyLate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2008;26(20):3418-25
63. PosaDas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinibinduced c-KIT moduLation in ovarian cancer: A phase II clinical study with proteomic profiling. Cancer 2007;110(2):309-17
64. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesyLate in patients with recurrent pLatinum-And taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101(1):126-31
65. Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesyLate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007;17(4):784-8
66. Matei D, Emerson RE, SchilDer J, et al. Imatinib mesyLate in combination with docetaxel for the treatment of patients with adVanced, pLatinum-resistant ovarian cancer and primary peritoneal carcinomatosis : A Hoosier Oncology Group trial. Cancer 2008;113(4):723-32
67. Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
68. Annunziata CM, Walker AJ, Minasian L, et al. VanDetanib, Designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no Detectable moduLation of VEGFR2. Clin Cancer Res 2010;16(2):664-72
69. Coleman RL, Moon J, Sood AK, et al. Randomised phase II study of docetaxel plus VanDetanib versus docetaxel followed by VanDetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 2014;50(9):1638-48
70. OMalley DM, Richardson DL, Rheaume PS, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;121(2):269-72
71. Cohn DE, Kim KH, Resnick KE, et al. Jr. At what cost does a potential survival adVantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29(10):1247-51
72. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115(3):396-400
73. Hecht JR, MitcheE, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27(5):672-80
74. Richardson DL, Backes FJ, Seamon LG, et al. Combination gemcitabine, pLatinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008;111(3):461-6
75. Herzog TJ, Armstrong DK, Brady MF, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014;132(1):8-17
76. Herzog TJ, Alvarez RD, Secord A, et al. SGO guiDance document for clinical trial Designs in ovarian cancer: A changing paradigm. Gynecol Oncol 2014;135(1):3-7
77. Chan JK, Herzog TJ, Hu L, et al. Bevacizumab in treatment of high-risk ovarian cancer-A cost-effectiveness analysis. Oncologist 2014;19(5):523-7
78. Gourley C, McCavigan A, Perren T, et al. MolecuLar subgroup of high-graDe serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014;32(5s Suppl):abstract 5502